The specific blockade of CML development caused by SOS1 ablation in p210BCR/ABL mice indicates that SOS1 is critically required for CML pathogenesis and supports the consideration of this cellular GEF as a novel, alternative bona fide therapeutic target for CML treatment in the clinic. The gene discussed is SOS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.